BPDCN is an uncommon haematological malignancy recognised as a distinct entity by the WHO in 2016. It typically presents with skin lesions and involves bone marrow, lymph nodes, and CNS, affecting all age groups. The disease poses significant diagnostic challenges, with limited data on optimal treatment strategies, further contributing to its dismal prognosis. Standard regimens include ALL-like or AML-like therapies, particularly in older adults. We outline our experiences managing three consecutive BPDCN patients, emphasising the unique challenges oncologists face when treating this malignancy. This underscores scarcity of effective therapies, limited expertise, and intricacies involved in managing such a complex disease.